당뇨병성 족부궤양 치료 시장 : 시장 규모, 점유율 및 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트 및 예측(2025-2034년)

Growth Factors of diabetic foot ulcer (DFU) treatment Market

The global diabetic foot ulcer (DFU) treatment market was valued at USD 9.36 billion in 2025 and is expected to grow to USD 9.92 billion in 2026. By 2034, the market is projected to reach USD 16.36 billion, registering a CAGR of 6.44% from 2026 to 2034. North America dominated the market in 2025 with a 38.88% share, fueled by the high prevalence of diabetic foot ulcers, rising awareness for early treatment, and growing collaborations to launch advanced treatment solutions.

Diabetic foot ulcers are common complications in patients with type 1 and type 2 diabetes, characterized by non-healing wounds typically on the feet. These ulcers can lead to severe infections and, in extreme cases, amputation. The DFU treatment market includes advanced wound dressings such as antimicrobials, hydrogel, and foam dressings, wound-care devices including negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBOT), active therapies like skin graft substitutes, and supportive products such as offloading devices.

Market Drivers

The market is primarily driven by the rising prevalence of diabetes and related foot ulcers. Globally, about 18.6 million people are affected annually, including 1.6 million in the U.S., highlighting the significant demand for advanced treatment options. The growing geriatric population, lifestyle changes, and obesity further contribute to the increasing incidence of DFUs.

Technological advancements and the introduction of innovative products also drive market growth. For instance, Smith+Nephew launched the RENASYS EDGE NPWT system in April 2024, a compact, homecare-friendly device for chronic wound treatment. Similarly, bioactive therapies such as skin grafting growth factors are enhancing wound healing and reducing recovery times.

Market Restraints

The high cost of advanced DFU treatments and the longer duration of wound recovery remain challenges. Severe ulcers can take up to 190 days to heal, increasing the economic burden on patients and healthcare systems. However, government reimbursement policies in developed countries mitigate some financial constraints, supporting the adoption of treatment products.

Market Trends

There is a shift from traditional to advanced wound management products. Advanced wound care dressings, including hydrocolloids, hydrogels, and antimicrobial dressings, promote faster healing by maintaining optimal moisture balance and controlling infections. Increasing R&D initiatives and product launches by key players further accelerate adoption. For example, Varco Leg Care launched Ulsr Soothe Max in December 2023, designed to treat DFUs and varicose vein ulcers efficiently.

Segmentation Analysis

By Ulcer Type: The market is segmented into neuro-ischemic, neuropathic, and ischemic ulcers. The neuro-ischemic segment dominated in 2026 with a 58.45% share, due to its prevalence and risk of severe complications if untreated. Neuropathic and ischemic ulcers also hold significant shares, driven by peripheral neuropathy and peripheral artery disease among diabetic patients.

By Product: Wound-care dressings accounted for the largest share in 2026 at 42.42%, due to ease of use, effective exudate management, and faster healing. Wound-care devices and active therapies are expected to grow steadily, with active therapies showing the highest CAGR due to increased awareness and adoption of bioactive and advanced treatment options.

By End-user: Hospitals held the largest share of 39.48% in 2026, reflecting patient preference for skilled care in clinical settings. Clinics, ambulatory surgical centers, and home care settings are also witnessing growth due to rising healthcare expenditure, reimbursement policies, and innovative homecare therapies such as Topical Wound Oxygen (TWO2) therapy approved by China's NMPA in 2022.

Regional Insights

North America led with a market size of USD 3.64 billion in 2025, with the U.S. projected to reach USD 3.56 billion by 2026, supported by high prevalence, advanced healthcare infrastructure, and collaborative initiatives. Europe held the second-largest share, with the U.K. and Germany projected to reach USD 0.34 billion and USD 0.7 billion respectively by 2026. Asia Pacific is expected to register the highest CAGR, driven by a rising geriatric population, lifestyle changes, and expansion by key players in Japan, China, and India. Latin America and the Middle East & Africa hold smaller shares but are expected to grow due to increased regulatory approvals and healthcare expenditure.

Competitive Landscape

The market is highly fragmented, with key players such as 3M, Smith+Nephew, Molnlycke Health Care AB, Cardinal Health, B. Braun SE, Convatec Inc., and Integra LifeSciences focusing on product innovation, strategic collaborations, acquisitions, and expanding global footprints. Recent developments include 3M FDA approvals in 2023 for advanced Veraflo Therapy dressings and Convatec's acquisition of Triad Life Sciences in 2022 to strengthen their biologics portfolio.

Report Coverage

The report provides a detailed overview of the DFU treatment market, including market drivers, restraints, trends, segmentation by ulcer type, product, and end-user, regional analysis, and competitive landscape, along with insights on healthcare expenditure, prevalence, and regulatory approvals. It also highlights the impact of COVID-19 and the recovery of the market post-pandemic.

Conclusion

The global diabetic foot ulcer treatment market, valued at USD 9.36 billion in 2025, is projected to grow to USD 9.92 billion in 2026 and reach USD 16.36 billion by 2034, reflecting a CAGR of 6.44% from 2026 to 2034. North America continues to lead the market, supported by the high prevalence of DFUs, advanced healthcare infrastructure, growing awareness for early intervention, and collaborative initiatives to launch innovative treatment solutions.

Market growth is primarily driven by the rising incidence of diabetes and associated foot ulcers, the expanding geriatric population, lifestyle changes, and increasing adoption of advanced wound care products. Technological advancements, including NPWT systems, hydrogel and antimicrobial dressings, and bioactive therapies, have enhanced treatment effectiveness, improved patient compliance, and shortened recovery times.

The shift from traditional to advanced wound management and the growing adoption of homecare-based therapies, such as Topical Wound Oxygen (TWO2) systems, are expanding market accessibility. While the high cost of treatment and longer healing durations pose challenges, reimbursement policies and increasing healthcare expenditure in developed regions mitigate these constraints.

Segmentation By Ulcer Type

• Neuropathic Ulcer
• Ischemic Ulcers
• Neuro-ischemic Ulcer

By Product

• Wound-care Dressings
  • Antimicrobial Dressings
  • Foam Dressings
  • Film Dressings
  • Alginate Dressings
  • Hydrogel Dressings
  • Other Dressings
• Wound-care Devices
  • Negative Pressure Wound Therapy (NPWT)
  • Ultrasound Therapy
  • Hyperbaric Oxygen Therapy (HBOT)
  • Others
• Active Therapies
  • Skin Grafts & Substitutes
  • Growth Factors
  • Others
• Others

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Homecare Settings

By Region

• North America (By Ulcer Type, By Product, By End User, and By Country)
  • U.S.
  • Canada
• Europe (By Ulcer Type, By Product, By End User, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Ulcer Type, By Product, By End User, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Ulcer Type, By Product, By End User, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa ( By Ulcer Type, By Product, By End User, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Diabetic Foot Ulcer (DFU) Patients, By Key Countries, 2025
• 4.2. Cost of Diabetic Foot Ulcer (DFU) Treatment, By Key Countries, 2025
• 4.3. Economic Cost Burden, Wound Care, By Key Countries, 2025/2025
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments: Mergers, Acquisitions, Partnerships
• 4.6. Impact of COVID-19 on the Global Diabetic Foot Ulcer Treatment Market

5. Global Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Ulcer Type
  • 5.1.1. Neuropathic Ulcer
  • 5.1.2. Ischemic Ulcers
  • 5.1.3. Neuro-Ischemic Ulcer
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Wound-care Dressings
    • 5.2.1.1. Antimicrobial Dressings
    • 5.2.1.2. Foam Dressings
    • 5.2.1.3. Film Dressings
    • 5.2.1.4. Alginate Dressings
    • 5.2.1.5. Hydrogel Dressings
    • 5.2.1.6. Other Dressings
  • 5.2.2. Wound-care Devices
    • 5.2.2.1. Negative Pressure Wound Therapy (NPWT)
    • 5.2.2.2. Ultrasound Therapy
    • 5.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 5.2.2.4. Others
  • 5.2.3. Active Therapies
    • 5.2.3.1. Skin Grafts & Substitutes
    • 5.2.3.2. Growth Factors
    • 5.2.3.3. Others
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Clinics
  • 5.3.3. Ambulatory Surgical Centers
  • 5.3.4. Homecare Settings
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Ulcer Type
  • 6.1.1. Neuropathic Ulcer
  • 6.1.2. Ischemic Ulcers
  • 6.1.3. Neuro-Ischemic Ulcer
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Wound-care Dressings
    • 6.2.1.1. Antimicrobial Dressings
    • 6.2.1.2. Foam Dressings
    • 6.2.1.3. Film Dressings
    • 6.2.1.4. Alginate Dressings
    • 6.2.1.5. Hydrogel Dressings
    • 6.2.1.6. Other Dressings
  • 6.2.2. Wound-care Devices
    • 6.2.2.1. Negative Pressure Wound Therapy (NPWT)
    • 6.2.2.2. Ultrasound Therapy
    • 6.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 6.2.2.4. Others
  • 6.2.3. Active Therapies
    • 6.2.3.1. Skin Grafts & Substitutes
    • 6.2.3.2. Growth Factors
    • 6.2.3.3. Others
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Clinics
  • 6.3.3. Ambulatory Surgical Centers
  • 6.3.4. Homecare Settings
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Ulcer Type
  • 7.1.1. Neuropathic Ulcer
  • 7.1.2. Ischemic Ulcers
  • 7.1.3. Neuro-Ischemic Ulcer
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Wound-care Dressings
    • 7.2.1.1. Antimicrobial Dressings
    • 7.2.1.2. Foam Dressings
    • 7.2.1.3. Film Dressings
    • 7.2.1.4. Alginate Dressings
    • 7.2.1.5. Hydrogel Dressings
    • 7.2.1.6. Other Dressings
  • 7.2.2. Wound-care Devices
    • 7.2.2.1. Negative Pressure Wound Therapy (NPWT)
    • 7.2.2.2. Ultrasound Therapy
    • 7.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 7.2.2.4. Others
  • 7.2.3. Active Therapies
    • 7.2.3.1. Skin Grafts & Substitutes
    • 7.2.3.2. Growth Factors
    • 7.2.3.3. Others
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Clinics
  • 7.3.3. Ambulatory Surgical Centers
  • 7.3.4. Homecare Settings
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Ulcer Type
  • 8.1.1. Neuropathic Ulcer
  • 8.1.2. Ischemic Ulcers
  • 8.1.3. Neuro-Ischemic Ulcer
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Wound-care Dressings
    • 8.2.1.1. Antimicrobial Dressings
    • 8.2.1.2. Foam Dressings
    • 8.2.1.3. Film Dressings
    • 8.2.1.4. Alginate Dressings
    • 8.2.1.5. Hydrogel Dressings
    • 8.2.1.6. Other Dressings
  • 8.2.2. Wound-care Devices
    • 8.2.2.1. Negative Pressure Wound Therapy (NPWT)
    • 8.2.2.2. Ultrasound Therapy
    • 8.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 8.2.2.4. Others
  • 8.2.3. Active Therapies
    • 8.2.3.1. Skin Grafts & Substitutes
    • 8.2.3.2. Growth Factors
    • 8.2.3.3. Others
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Clinics
  • 8.3.3. Ambulatory Surgical Centers
  • 8.3.4. Homecare Settings
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Ulcer Type
  • 9.1.1. Neuropathic Ulcer
  • 9.1.2. Ischemic Ulcers
  • 9.1.3. Neuro-Ischemic Ulcer
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Wound-care Dressings
    • 9.2.1.1. Antimicrobial Dressings
    • 9.2.1.2. Foam Dressings
    • 9.2.1.3. Film Dressings
    • 9.2.1.4. Alginate Dressings
    • 9.2.1.5. Hydrogel Dressings
    • 9.2.1.6. Other Dressings
  • 9.2.2. Wound-care Devices
    • 9.2.2.1. Negative Pressure Wound Therapy (NPWT)
    • 9.2.2.2. Ultrasound Therapy
    • 9.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 9.2.2.4. Others
  • 9.2.3. Active Therapies
    • 9.2.3.1. Skin Grafts & Substitutes
    • 9.2.3.2. Growth Factors
    • 9.2.3.3. Others
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Ambulatory Surgical Centers
  • 9.3.4. Homecare Settings
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Ulcer Type
  • 10.1.1. Neuropathic Ulcer
  • 10.1.2. Ischemic Ulcers
  • 10.1.3. Neuro-Ischemic Ulcer
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. Wound-care Dressings
    • 10.2.1.1. Antimicrobial Dressings
    • 10.2.1.2. Foam Dressings
    • 10.2.1.3. Film Dressings
    • 10.2.1.4. Alginate Dressings
    • 10.2.1.5. Hydrogel Dressings
    • 10.2.1.6. Other Dressings
  • 10.2.2. Wound-care Devices
    • 10.2.2.1. Negative Pressure Wound Therapy (NPWT)
    • 10.2.2.2. Ultrasound Therapy
    • 10.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
    • 10.2.2.4. Others
  • 10.2.3. Active Therapies
    • 10.2.3.1. Skin Grafts & Substitutes
    • 10.2.3.2. Growth Factors
    • 10.2.3.3. Others
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals
  • 10.3.2. Clinics
  • 10.3.3. Ambulatory Surgical Centers
  • 10.3.4. Homecare Settings
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Coloplast A/S
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Smith+Nephew
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. 3M
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Convatec Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Integra LifeSciences
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. B. Braun SE
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Cardinal Health
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Molnlycke Health Care AB
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Essity Aktiebolag (publ).
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)